Companies are cutting payments to shareholders at a rate not seen since 2009
While advisers generally tell clients to stay the course, there are few products that reward those who do
The stock market eroded account balances, but savers increased their contributions
Broker-dealers are pausing the sale of real estate products while the broader market absorbs the shock of the shutdown
The new chief commercial officer position signals a focus on holistic planning
When fund managers rejigger their methodology, investors don't know how to calculate returns
The firm will act as a fiduciary for insurance provider selection for qualified longevity annuity contracts
Mitch McConnell's comment came as Congress considers extending aid to cities and states that are seeing tax revenue disappear as wide swaths of the economy are shut down
The Pacer fund could invest in stocks of businesses that identify or combat diseases or companies that enable social distancing
Somerset Securities recently filed a case against the insurer over its 2018 decision to halt trail commissions on certain variable annuity contracts
Low interest rates drove investors away from some products, but that may change, according to the organization's Secure Retirement Institute
InvestmentNews Chief Content Officer George Moriarty looks at why some broker-dealers are halting sales of real estate products and whether the rush to gold will continue
The United States Oil Fund had to suspend the issuance of new shares after losing a third of its value in two days
The insurer added a new low-cost variable annuity product without living benefits
Report says lower trading costs will encourage advisers to use exchange-traded funds for niche asset allocations
The coronavirus is throwing a wrench in many Americans' financial plans, but advisers can help keep investors on track
New thematic funds offer expense ratios that drop over time
Regulator says Old Ironsides distributed materials with misleading information
The end of the formal initiative failed to soothe worries about future enforcement
Pharmaceutical Product Development mismanaged its 401(k) plan, opting for costlier investments than necessary, plaintiffs say
